Previous Close | 0.2820 |
Open | 0.2800 |
Bid | 0.2800 x 1200 |
Ask | 0.2850 x 800 |
Day's Range | 0.2800 - 0.2896 |
52 Week Range | 0.0920 - 0.6500 |
Volume | |
Avg. Volume | 836,770 |
Market Cap | 8.842M |
Beta (5Y Monthly) | 1.73 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.9320 |
Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Sept 21, 2022 |
1y Target Est | 16.00 |
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21
Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...
Over the last year, a good number of insiders have significantly increased their holdings in Catalyst Biosciences, Inc...